Subtype
Neuroendocrine Carcinoma
CI-CAN-00001275NECExplore in graph →
515 active trials12 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001275NECExplore in graph →
Clinical trials
1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (213)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06292988 | Predictive Factors for Medullary Thyroid Cancer Aggressiveness(MYELO) | completed | — | 500 | Aristotle University Of ThessalonikiOTHER | 24 | Jan 3, 2025 | clinicaltrials |
| NCT03837977 | Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma(NET02) | completed | Phase 2 | 58 | The Christie NHS Foundation TrustOTHER |
| 1 |
| Dec 30, 2024 |
| clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03043599 | Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT01945762 | Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer(Caprelsa104) | completed | — | 31 | Genzyme, a Sanofi CompanyINDUSTRY | 8 | Dec 18, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05933863 | Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance(MOSAIC) | completed | — | 168 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT04830813 | Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | completed | Phase 3 | 184 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06663852 | ML Decision Model for G-NEC Adjuvant Therapy(G-NEC) | completed | — | 1,505 | Chang-Ming Huang, Prof.OTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04920981 | Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC(CLINATEZO) | completed | — | 518 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04504669 | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | completed | Phase 1 | 60 | AstraZenecaINDUSTRY | 4 | Nov 5, 2024 | clinicaltrials |
| NCT05304793 | Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer | completed | N/A | 46 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04952597 | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer | completed | Phase 2 | 126 | BeiGeneINDUSTRY | 3 | Oct 26, 2024 | clinicaltrials |
| NCT03958045 | Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | completed | Phase 2 | 33 | Zhonglin HaoOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03583086 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | completed | Phase 1 / Phase 2 | 88 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | completed | Phase 2 | 647 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04768296 | Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) | completed | Phase 2 | 76 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 7 | Sep 26, 2024 | clinicaltrials |
| NCT04160065 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | completed | Phase 1 | 23 | TuHURA Biosciences, Inc.INDUSTRY | 1 | Sep 23, 2024 | clinicaltrials |
| NCT00686985 | Docetaxel - Carboplatin As Second Line Treatment in Patients with Small Cell Lung Cancer(DOCAR) | completed | Phase 2 | 50 | Dr. B. BiesmaOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT04434482 | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 59 | Impact Therapeutics, Inc.INDUSTRY | 5 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02815592 | Trial of BMS-986012 in Combination With Platinum and Etoposide | completed | Phase 1 | 12 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 4, 2024 | clinicaltrials |
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06550518 | Real-life Second-line Epirubicin-Paclitaxel Regimen as Treatment of Relapsed Small-Cell Lung Cancer : EpiTax Study.(EPITAX) | completed | — | 29 | University Hospital, BrestOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03417895 | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy(PASSION) | completed | Phase 2 | 59 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT01357395 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer(ESCAPE) | completed | Phase 2 | 23 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT04622228 | Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer(Match) | completed | Phase 2 | 56 | Hoffmann-La RocheINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04854590 | IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer | completed | — | 248 | AstraZenecaINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04028050 | A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer(MAURIS) | completed | Phase 3 | 155 | Hoffmann-La RocheINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05371899 | Mass Balance Study of [14C]Chiauranib | completed | N/A | 6 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT04727853 | Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 66 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04902885 | Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients | completed | Phase 3 | 95 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT01856920 | QUILT-3.006 for Recurrent Medullary Thyroid Cancer | completed | Phase 2 | 35 | NantCell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04730999 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer(CeLEBrATE) | completed | Phase 2 | 54 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT02978404 | Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases | completed | Phase 2 | 26 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02200757 | Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer | completed | Phase 2 | 135 | ImmunityBio, Inc.INDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT05116007 | Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC | completed | Phase 1 | 35 | AkesoINDUSTRY | 1 | May 31, 2024 | clinicaltrials |
| NCT03629756 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | completed | Phase 1 | 48 | Arcus Biosciences, Inc.INDUSTRY | 2 | May 24, 2024 | clinicaltrials |
| NCT04079595 | Closed vs. Open Face Masks for Cranial Radiotherapy | completed | N/A | 60 | University of ZurichOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02164461 | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | completed | Phase 1 | 12 | Advaxis, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT01941316 | Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients | completed | Phase 1 / Phase 2 | 78 | Cancer Research and Biostatistics Clinical Trials ConsortiumNETWORK | 1 | May 9, 2024 | clinicaltrials |
| NCT04324437 | eRAPID: Online Symptom Reporting in Lung Cancer | completed | N/A | 43 | University of LeedsOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04393753 | Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1(MERKLIN2) | completed | Phase 2 | 19 | 4SC AGINDUSTRY | 6 | May 8, 2024 | clinicaltrials |
| NCT05253144 | Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC(Rational-MCC) | completed | N/A | 64 | University of BirminghamOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04381910 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | completed | Phase 2 | 66 | Luye Pharma Group Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2025source: clinicaltrials